Summary & Overview
HCPCS J0184: Injection, Amisulpride, 1 mg
HCPCS Level II code J0184 designates injection, amisulpride, billed per 1 mg unit. This code is used when amisulpride is administered as a parenteral antipsychotic medication in clinic, outpatient infusion, or inpatient settings. Nationally, accurate coding of injectable psychotropic agents like amisulpride matters for clinical documentation, payer adjudication, and pharmacy billing workflows given variations in unitization and site-of-service rules.
Key payers discussed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for amisulpride injections, typical sites of service, common billing modifiers and administrative considerations (listed elsewhere in the publication), and what to expect from payer coverage and claims adjudication at a national level. The publication also outlines benchmarks for unit reporting, coding validation steps, and points of policy attention when administering and billing injectable antipsychotics.
This summary is intended for clinicians, billing professionals, and policy analysts seeking a focused reference on HCPCS Level II code J0184 and its role in billing injectable amisulpride across major national payers. Data not available in the input where applicable.
Billing Code Overview
HCPCS Level II code J0184 represents an injectable formulation of amisulpride, billed per 1 mg unit. The service type is an injection/infusion medication administration for a psychotropic antipsychotic agent. The typical site of service for this code is outpatient infusion or clinic-based injection administration; inpatient administration is also possible depending on clinical setting and facility practices.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 42-year-old outpatient with treatment-resistant schizophrenia presents to a behavioral health clinic for intramuscular injection therapy with amisulpride. The patient has inadequate response to oral antipsychotics and significant adherence barriers. The clinic visit includes psychiatric evaluation, informed consent review, medication reconciliation, preparation of the injectable formulation, and administration of J0184 (injection, amisulpride, 1 mg). Post-injection observation for 15–30 minutes monitors for acute adverse reactions (extrapyramidal symptoms, sedation, orthostatic hypotension). Documentation includes indication, dose, lot number, route, site of injection, patient tolerance, and billing with any applicable modifier(s). Typical clinicians involved are psychiatrists, psychiatric nurse practitioners, and registered nurses in an outpatient behavioral health or community mental health center. Typical site of service is an outpatient clinic or ambulatory behavioral health center; inpatient administration may occur in psychiatric units when clinically indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier / service not specified by other modifier | Use when no additional circumstances apply to the service billed with J0184. |